Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas
Repligen Corporation · Pancreatitis
Phase 3
Completed
258
2009-12
Industry sponsor intelligence
Repligen CorporationClinical Pipeline.
Lead-sponsor view of Repligen Corporation's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 3
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 0
- Avg enrollment
- 258
Pipeline overview
Programs by phase and activity.
Velocity
Repligen Corporation trials by start year
Study start year · indexed snapshot
Development
Trials by phase
3phase labels
Early Phase 10
Phase 10
Phase 20
Phase 33
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Secretin → | 3 | 0 | 0 | 3 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Synthetic Human Secretin in Children With Autism
Repligen Corporation · Autism
Phase 3
Completed
—
2005-08
Search sponsor records
All Repligen Corporation studies.
This page groups studies where Repligen Corporation is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
3 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT00660335Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the PancreasDec 3, 2009NCT00036231Synthetic Human Secretin in Children With Autism and Gastrointestinal DysfunctionNov 21, 2005NCT00036244Synthetic Human Secretin in Children With AutismAug 5, 2005